Patents by Inventor Omer SHKEDI

Omer SHKEDI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
    Patent number: 11060092
    Abstract: A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 13, 2021
    Assignees: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, RAMBAM MED-TECH LTD.
    Inventors: Izhak Kehat, Alon Abend, Omer Shkedi, Lilac Caspi
  • INHIBITORS OF CYTOPLASMIC HISTONE DEACETYLASE 4 COMPLEX FOR TREATING OR PREVENTING VASCULAR OR VALVE CALCIFICATION
    Publication number: 20190309300
    Abstract: A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA.
    Type: Application
    Filed: July 13, 2017
    Publication date: October 10, 2019
    Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., RAMBAM MED-TECH LTD.
    Inventors: Izhak KEHAT, Alon ABEND, Omer SHKEDI, Lilac CASPI